Detalles de la búsqueda
1.
Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
Clin Gastroenterol Hepatol;
22(3): 488-498.e14, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775028
2.
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.
Hepatology;
78(6): 1858-1866, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37203233
3.
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis.
Hepatology;
77(5): 1746-1756, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36633913
4.
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease.
Hepatol Res;
2024 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400797
5.
Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021.
Hepatol Res;
2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38638067
6.
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Hepatol Res;
2024 Jan 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38234088
7.
Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
J Gastroenterol Hepatol;
2024 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494668
8.
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
Gut;
72(11): 2138-2148, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37491159
9.
Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD.
Clin Gastroenterol Hepatol;
21(2): 380-387.e3, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123096
10.
Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.
Gastroenterology;
163(4): 1079-1089.e5, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35788349
11.
Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants.
Am J Gastroenterol;
118(4): 645-653, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36191268
12.
Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy.
J Viral Hepat;
30(4): 297-302, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648382
13.
Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.
Hepatology;
75(3): 661-672, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34496054
14.
Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
J Med Virol;
95(1): e28210, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36222204
15.
Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.
Hepatology;
75(6): 1647-1661, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34990037
16.
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Invest New Drugs;
41(2): 340-349, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36995548
17.
Complete alcohol abstinence increases the risk of NAFLD but not severity. A population analysis with transient elastography.
Scand J Gastroenterol;
58(1): 76-82, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35944527
18.
Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease.
BMC Gastroenterol;
23(1): 211, 2023 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37330485
19.
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B.
Hepatol Res;
53(1): 35-42, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36117296
20.
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Hepatol Res;
53(1): 61-71, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36070216